Pharmadigm Closes $3 Million Series B Financing; Pharmadigm Changes Corporate Name To Inflabloc Pharmaceuticals Inc.
10/19/2005 5:11:41 PM
Pharmadigm announced today that it has successfully completed a $3 million Series B venture financing. The funding round was co-led by Friedli Corporate Finance and vSpring Capital. Pharmadigm will use the financing to initiate Phase II clinical studies of its lead product targeting Crohn's disease, as well as to continue development in other inflammatory therapeutic areas. To reflect the company's new direction and focus, in conjunction with this financing, Pharmadigm changed its corporate name to Inflabloc Pharmaceuticals Inc. ("Inflabloc").
comments powered by